ArticleChemical science2019
Mitochondria-targeting fluorescent molecules for high efficiency cancer growth inhibition and imaging.
Article in Chemical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Targeted Nanoboron Delivery Platform for Boron Neutron Capture Therapy in Refractory Solid Tumors.International journal of nanomedicine · 2026Review
- Article
- Mitochondria-Targeted Nanosystems in the Treatment of Central Nervous System Diseases.International journal of nanomedicine · 2025Review
- Synthesis of a novel mitochondrial fluorescent probe - killing cancer cellsFrontiers in pharmacology · 2025Article
- Facile construction of dual-response super-resolution probes for tracking organelles dynamics.Exploration (Beijing, China) · 2024Article
- Article
- Recent advances in mitochondria-targeting theranostic agents.Exploration (Beijing, China) · 2024Review
- Toxic Effects of Penetrating Cations.Membranes · 2023Review
- Fatty Acid-Activated Proton Transport by Bisaryl Anion Transporters Depolarises Mitochondria and Reduces the Viability of MDA-MB-231 Breast Cancer Cells.Biomolecules · 2023Article
- Activation of pyroptosis by specific organelle-targeting photodynamic therapy to amplify immunogenic cell death for anti-tumor immunotherapy.Bioactive materials · 2023Article
- Recent Advances inMolecules (Basel, Switzerland) · 2023Review
- Bioinspired large Stokes shift small molecular dyes for biomedical fluorescence imaging.Science advances · 2022Article
- The Molecular Diversity of 1H-Indole-3-Carbaldehyde Derivatives and Their Role in Multicomponent Reactions.Topics in current chemistry (Cham) · 2022Review
- Unique assembly of carbonylpyridinium and chromene reveals mitochondrial thiol starvation under ferroptosis and novel ferroptosis inducer.Chemical science · 2022Article
- Is the Mitochondrial Membrane Potential (∆Ψ) Correctly Assessed? Intracellular and Intramitochondrial Modifications of the ∆Ψ Probe, Rhodamine 123.International journal of molecular sciences · 2022Article
- Exploring the therapeutic potential of mitochondrial uncouplers in cancer.Molecular metabolism · 2021Review
- A dual-labeling probe to track functional mitochondria-lysosome interactions in live cells.Nature communications · 2020Article
- All-in-one mitochondria-targeted NIR-II fluorophores for cancer therapy and imaging.Chemical science · 2020Article
- A NIR-I light-responsive superoxide radical generator with cancer cell membrane targeting ability for enhanced imaging-guided photodynamic therapy.Chemical science · 2020Article
- Soft Mesoporous Organosilica Nanoplatforms Improve Blood Circulation, Tumor Accumulation/Penetration, and Photodynamic Efficacy.Nano-micro letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Fluorescent mitochondria-accumulating delocalized lipophilic cations (DLCs) for cancer therapy have drawn significant attention in the field of cancer theranostics. One of the most promising fluorescent DLCs, F16, can selectively trigger the apoptosis and necrosis of cancer cells, making it an attractive targeted theranostic drug candidate. However, it suffers from low clinical translation potential, largely due to its inefficient anti-cancer activity (IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.